Current status of potential therapeutic candidates for the COVID-19 crisis

被引:188
作者
Zhang, Jiancheng [1 ,2 ]
Xie, Bing [2 ]
Hashimoto, Kenji [1 ]
机构
[1] Chiba Univ, Div Clin Neurosci, Ctr Forens Mental Hlth, 1-8-1 Inohana, Chiba 2608670, Japan
[2] Huazhong Univ Sci & Technol, Dept Crit Care Med, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China
基金
日本学术振兴会;
关键词
ACE2; blocker; Antimalaria; Antiviral: Chinese traditional medicine; COVID-19; Immunoenhancer; Monoclonal antibody; Vaccine; MESENCHYMAL STEM-CELLS; ACUTE RESPIRATORY SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; ACUTE LUNG INJURY; SARS-CORONAVIRUS INFECTION; ENDOTHELIAL GROWTH-FACTOR; CRITICALLY-ILL PATIENTS; EBOLA-VIRUS INFECTION; INHALED NITRIC-OXIDE; INTERFERON-BETA;
D O I
10.1016/j.bbi.2020.04.046
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness.
引用
收藏
页码:59 / 73
页数:15
相关论文
共 228 条
[1]   Complications of intravenous immune globulin treatment in neurologic disease [J].
Achiron, A .
NEUROLOGY, 1997, 49 (03) :899-900
[2]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[3]   Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance [J].
Agostini, Maria L. ;
Pruijssers, Andrea J. ;
Chappell, James D. ;
Gribble, Jennifer ;
Lu, Xiaotao ;
Andres, Erica L. ;
Bluemling, Gregory R. ;
Lockwood, Mark A. ;
Sheahan, Timothy P. ;
Sims, Amy C. ;
Natchus, Michael G. ;
Saindane, Manohar ;
Kolykhalov, Alexander A. ;
Painter, George R. ;
Baric, Ralph S. ;
Denison, Mark R. .
JOURNAL OF VIROLOGY, 2019, 93 (24)
[4]   Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease [J].
Agostini, Maria L. ;
Andres, Erica L. ;
Sims, Amy C. ;
Graham, Rachel L. ;
Sheahan, Timothy P. ;
Lu, Xiaotao ;
Smith, Everett Clinton ;
Case, James Brett ;
Feng, Joy Y. ;
Jordan, Robert ;
Ray, Adrian S. ;
Cihlar, Tomas ;
Siegel, Dustin ;
Mackman, Richard L. ;
Clarke, Michael O. ;
Baric, Ralph S. ;
Denison, Mark R. .
MBIO, 2018, 9 (02)
[5]   Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) [J].
Ahn, Dae-Gyun ;
Shin, Hye-Jin ;
Kim, Mi-Hwa ;
Lee, Sunhee ;
Kim, Hae-Soo ;
Myoung, Jinjong ;
Kim, Bum-Tae ;
Kim, Seong-Jun .
JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2020, 30 (03) :313-324
[6]   Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus [J].
Åkerström, S ;
Mousavi-Jazi, M ;
Klingström, J ;
Leijon, M ;
Lundkvist, Å ;
Mirazimi, A .
JOURNAL OF VIROLOGY, 2005, 79 (03) :1966-1969
[7]   Baricitinib: A Review in Rheumatoid Arthritis [J].
Al-Salama, Zaina T. ;
Scott, Lesley J. .
DRUGS, 2018, 78 (07) :761-772
[8]  
ANDERSSON JP, 1990, IMMUNOLOGY, V71, P372
[9]  
ANDERSSON UG, 1993, IMMUNOLOGY, V79, P211
[10]  
[Anonymous], 2020, NIH CLIN TRIAL INV V